Nicola A. Hanania, MD, MS
Baylor College of Medicine
H-index: 81
North America-United States
Top articles of Nicola A. Hanania, MD, MS
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Efficacité et sécurité du dupilumab chez des patients atteints de BPCO avec une inflammation de type 2 (élévation des éosinophiles) | Revue des Maladies Respiratoires Actualités | S Bhatt G Devouassoux K Rabe N Hanania C Vogelmeier | 2024/1/1 |
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population | The Journal of Allergy and Clinical Immunology: In Practice | Jonathan Corren Stanley J Szefler Ellen Sher Phillip Korenblat Weily Soong | 2024/2/14 |
Predicting Severe Asthma Attacks With Blood Eosinophils and Exhaled Nitric Oxide (FeNO): Initial Data Analysis for the ORACLE Patient-level Meta-analysis | S Couillard FL Meulmeester CA Celis-Preciado S Ramakrishnan G Brusselle | 2024/5 | |
Social Determinants of Health Associated With Frailty in Smokers: Analysis of the COPDGene Cohort | EK Phillips EA Regan BJ Make AM Yohannes JD Crapo | 2024/5 | |
Dupilumab Does Not Impact Blood Eosinophil Levels in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: From the Phase 3 Boreas Trial | M Bafadhel SA Christenson NA Hanania SP Bhatt KF Rabe | 2024/5 | |
Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020–2023 | Lung | Maria Gabriella Matera Luigino Calzetta Paola Rogliani Nicola Hanania Mario Cazzola | 2024/2/6 |
Early evidence of chronic obstructive pulmonary disease obscured by race-specific prediction equations | American journal of respiratory and critical care medicine | Elizabeth A Regan Melissa E Lowe Barry J Make Jeffrey L Curtis Quan Chen | 2024/1/1 |
Sex differences and determinants of anxiety symptoms in patients with COPD initiating pulmonary rehabilitation. | Respiratory Medicine | Abebaw M Yohannes R Casaburi S Dryden NA Hanania | 2024/4/15 |
In the Phase 3 Boreas Trial, Baseline Blood Eosinophils and Baseline Fractional Exhaled Nitric Oxide Levels Predict the Response to Dupilumab in Patients With Moderate-to … | S Christenson NA Hanania SP Bhatt M Bafadhel KF Rabe | 2024/5 | |
Dupilumab Improves Post-bronchodilator Lung Function in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the … | NA Hanania SP Bhatt KF Rabe CF Vogelmeier M Bafadhel | 2024/5 | |
Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils | CHEST | Surya P Bhatt Klaus F Rabe Nicola A Hanania Claus F Vogelmeier Jeremy Cole | 2023/10/1 |
Association Of Baseline Lung Function And Likelihood Of Oral Corticosteroid Reduction In Patients With OCS-Dependent Severe Asthma | Journal of Allergy and Clinical Immunology | Christian Domingo Nicola Hanania Giorgio Canonica David Halpin Njira Lugogo | 2024/2/1 |
Efficacy of Mepolizumab in Patients With COPD and an Eosinophilic Phenotype With Chronic Bronchitis-A Post Hoc Analysis of the METREX & METREO Phase 3 Studies | GJ Criner NA Hanania F Maltais F Martinez M Bafadhel | 2024/5 | |
In The Phase 3 Boreas Trial, Dupilumab Reduced FeNO Levels Over Time in Patients With Moderate-to-Severe COPD With Type 2 Inflammation | SP Bhatt SA Christenson NA Hanania M Bafadhel KF Rabe | 2024/5 | |
Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma | Respiratory Medicine | Nicole M Chase Monica Littlejohn Cecile TJ Holweg Lauren A Millette Arpamas Seetasith | 2024/3/1 |
Real-Life Patterns of Biologic Use and Switch for Severe Asthma at a Major County Hospital | Journal of Allergy and Clinical Immunology | Rubabin Tooba Aaron Pathak Mohammad Bilal Nicola Hanania Muhammad Adrish | 2024/2/1 |
Dupilumab Increases the Proportion of Patients With Fractional Exhaled Nitric Oxide Levels< 20 ppb Over Time in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary … | S Christenson M Bafadhel NA Hanania SP Bhatt KF Rabe | 2024/5 | |
Efficacy and Safety of Dupilumab in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: Phase 3 NOTUS Trial | JAMA dermatology | Amy S Paller Jonathan I Silverberg Michael J Cork Emma Guttman-Yassky Benjamin Lockshin | 2023/3/1 |
An Update on Patient-Reported Outcomes in Asthma | Tianshi David Wu Zuzana Diamant Nicola A Hanania | 2024/2/15 | |
Influence of baseline bronchodilator reversibility and blood eosinophils on lung function in patients with asthma following omalizumab | The Journal of Allergy and Clinical Immunology: In Practice | Thomas B Casale Bradley E Chipps Ahmar Iqbal Bongin Yoo Lauren A Millette | 2024/2/1 |
Co-Authors
